FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054694018> ?p ?o ?g. }

• W2054694018 endingPage "266" @default.
• W2054694018 startingPage "265" @default.
• W2054694018 abstract "Specificity is at the heart of immunology and so is the distinction between self and non-self. Cancer cells develop from self, i.e., normal cells of the host, but only after the cells have accumulated numerous heritable epigenetic changes. In addition, there are mutational changes leading to tumour-specific proteins and potential antigens. Finding molecular targets exclusively expressed on cancer cells is one of the great hopes of cancer medicine. Targeting such tumour-specific molecules should eradicate cancer without systemic toxicity.There is no question that all cancers in man and mouse that have been carefully analyzed express truly tumor-specific antigens that could be targeted [2]. The diversity of these antigens on cancer cells led Macfarlane Burnet to postulate that adaptive immunity evolved to cope with and prevent the development of primary cancers [3]. This concept of immune surveillance continues to stimulate not only research but also controversy regarding its general validity. Clearly, sporadic cancers can develop in normal immunocompetent hosts while retaining strong tumor-specific rejection antigens without evidence of immunoselection [4, 5].Increasing numbers of tumor-specific mutant proteins have been identified, and the same tumor types may share some mutations. One prominent example is given by the review of Sampson et al. on targeting a EGFRvIII mutation that is widely expressed in malignant glioma and other neoplasms. The targeted mutant molecule is a constitutively active tyrosine-kinase that increases tumorigenicity and confers radiation and drug resistance. As a result of immune selection, the mutant receptor can undergo additional mutations to evade immune destruction while maintaining its tumor-promoting function. Predicting these variants and vaccinating against them before they occur may prevent tumor escape [6]. Other examples of certain tumor types sharing mutations are clear cell sarcomas, some of the most aggressive human cancers. Cancer type-specific translocations encode distinct fusion proteins in these sarcomas [7, 8]. It is likely that we are only beginning to realize the enormous opportunities of targeting tumor-specific molecules on cancer cells resulting from mutations shared among diverse cancers. This becomes evident by the review by Schietinger et al. that discusses the discovery of mutations in a chaperone Cosmc. These mutations in diverse human and murine cancer types result in tumour-specific glycopeptidic neo-epitopes recognized on the cancer cells by tumor-specific antibodies.In addition to some mutations being shared by different cancers, each individual’s cancer seems to have its own unique set of T cell-recognized antigens and somatic tumor-specific mutations and epitopes [9–13] some of which represent powerful rejection antigens [14]. In a landmark paper [15], Klein et al. showed decades ago that mice could be immunized to their own, i.e., autochthonous, cancers; eradication only occurred when the autochthonous cancer cells were used for immunization against subsequent challenge with the same tumor. Despite the power of Klein’s observation, unique antigens have remained largely unexploited therapeutically because highly personalized therapy would be required. While the molecular identification of these unique antigens is probably not necessary for successful therapy, it is worthwhile to improve ways to immunologically target these antigens in patients. This is also suggested by the review of Neller et al. who show that whole cell vaccine or cell extracts yielded twice the number of patients with a beneficial clinical response than vaccines using molecularly defined antigens. Clearly, autologous dendritic cells loaded with autologous tumor antigen are attractive vaccines. As discussed by Buckwalter and Srivastava in their review, immunization with heat-shock-protein-peptide complexes is an alternative approach of immunizing against individually specific antigens without needing antigen identification. In my long experience of immunizing against individually specific antigens on murine tumours, viable cancer cells at a sublethal dose are usually most effective in causing robust, specific T cell immunity. Irradiated cancer cells, are usually less effective immunogens while tumor cell extracts seem to be the most difficult material for inducing specific and strong T cell responses. For therapy of cancer patients, obtaining viable cancer cells is usually still extremely problematic because of a remarkable, persistent difficulty with most primary human cancers of isolating cancer cells that can be propagated in vitro. Therefore the question arises whether immune responses to certain tumor-associated antigens (non-mutant, normal-self antigens) can be utilized as “adjuvant” to make patient’s immune system “aware” of other antigens on their cancer cells including the individually specific mutant tumor antigens. In their comprehensive review, Coulie and Lucas discuss interesting data supporting this attractive idea.All of the reviews in this Issue argue that clinically significant advances with immunotherapy are most likely first to occur in patients with minimal residual tumor load. However, as well known from infectious disease, active immunization in patients that are already infected rarely succeeds (except in the special case of rabies) and minimal number of cancer cells persisting in the patient may cause significant difficulties of inducing destructive immune responses. On the other hand, we have clear evidence from adoptive T cell transfer with EBV-antigen specific T cells, that large, bulky, metastatic, chemotherapy- and radiation-resistant EBV antigen-positive cancers can be eradicated in patients without side effects [16]. It would be important to develop procedures for immunizing and expanding in vitro patients’ own lymphocytes so that they recognize the autochthonous tumor cells specifically. The induced T cells may not only be therapeutic upon reinfusion but also be used to further elucidate genetic origins of tumor-specific mutant tumor antigens. While quite effective drugs are being generated for targeting specific mutations, and while cancer treatment is getting “personal” [17], it seems ironic that individual specificity still has to conquer the field of cancer immunology although it was precisely the discovery of individually distinct tumor-specific antigens that ended the gloom over the field of cancer immunology [10, 14, 15, 18]. “I cannot give any scientist of any age better advice that this: The intensity of the conviction that a hypothesis is true has no bearing on whether it is true or not. The importance of the strength of our conviction is only to provide a proportionally strong incentive to find out if the hypothesis will stand up to critical evaluation.” Sir Peter B. Medawar Advice to a young scientist. 1979, page 39. [1]" @default.
• W2054694018 created "2016-06-24" @default.
• W2054694018 creator A5000018452 @default.
• W2054694018 date "2008-10-01" @default.
• W2054694018 modified "2023-10-16" @default.
• W2054694018 title "Tumor-specific immune responses" @default.
• W2054694018 cites W1483194800 @default.
• W2054694018 cites W1592224632 @default.
• W2054694018 cites W1598359965 @default.
• W2054694018 cites W183894410 @default.
• W2054694018 cites W1983664228 @default.
• W2054694018 cites W2055372756 @default.
• W2054694018 cites W2084238041 @default.
• W2054694018 cites W2087304127 @default.
• W2054694018 cites W2087751238 @default.
• W2054694018 cites W2104224322 @default.
• W2054694018 cites W2109472720 @default.
• W2054694018 cites W2112086944 @default.
• W2054694018 cites W2121768186 @default.
• W2054694018 cites W2127510227 @default.
• W2054694018 cites W4238448376 @default.
• W2054694018 doi "https://doi.org/10.1016/j.smim.2008.10.001" @default.
• W2054694018 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3644555" @default.
• W2054694018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18977672" @default.
• W2054694018 hasPublicationYear "2008" @default.
• W2054694018 type Work @default.
• W2054694018 sameAs 2054694018 @default.
• W2054694018 citedByCount "2" @default.
• W2054694018 countsByYear W20546940182012 @default.
• W2054694018 crossrefType "journal-article" @default.
• W2054694018 hasAuthorship W2054694018A5000018452 @default.
• W2054694018 hasBestOaLocation W20546940182 @default.
• W2054694018 hasConcept C203014093 @default.
• W2054694018 hasConcept C70721500 @default.
• W2054694018 hasConcept C86803240 @default.
• W2054694018 hasConcept C8891405 @default.
• W2054694018 hasConceptScore W2054694018C203014093 @default.
• W2054694018 hasConceptScore W2054694018C70721500 @default.
• W2054694018 hasConceptScore W2054694018C86803240 @default.
• W2054694018 hasConceptScore W2054694018C8891405 @default.
• W2054694018 hasIssue "5" @default.
• W2054694018 hasLocation W20546940181 @default.
• W2054694018 hasLocation W20546940182 @default.
• W2054694018 hasLocation W20546940183 @default.
• W2054694018 hasLocation W20546940184 @default.
• W2054694018 hasOpenAccess W2054694018 @default.
• W2054694018 hasPrimaryLocation W20546940181 @default.
• W2054694018 hasRelatedWork W1722749129 @default.
• W2054694018 hasRelatedWork W2050283198 @default.
• W2054694018 hasRelatedWork W2141330728 @default.
• W2054694018 hasRelatedWork W2152260884 @default.
• W2054694018 hasRelatedWork W2220102944 @default.
• W2054694018 hasRelatedWork W2577548098 @default.
• W2054694018 hasRelatedWork W282825803 @default.
• W2054694018 hasRelatedWork W3007075535 @default.
• W2054694018 hasRelatedWork W3031852375 @default.
• W2054694018 hasRelatedWork W3112940496 @default.
• W2054694018 hasVolume "20" @default.
• W2054694018 isParatext "false" @default.
• W2054694018 isRetracted "false" @default.
• W2054694018 magId "2054694018" @default.
• W2054694018 workType "article" @default.